NOVO NORDISK A S

NOVO NORDISK A S (NVO) is a US-listed equity tracked across major market indices. With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

FINOTAUR provides free research summaries, news aggregation, and fundamentals for NVO to support both active traders and long-term investors.